Amyris: Well Positioned In The Cannabinoids Market

Dec. 17, 2021 10:28 AM ETAmyris, Inc. (AMRSQ) StockAMRSQ17 Comments
Richard Durant
8.84K Followers

Summary

  • Amyris is the only synthetic biology company developing and manufacturing a portfolio of products at scale.
  • Biosynthesis of cannabinoids reduces regulatory concerns and makes minor cannabinoids commercially viable.
  • The cannabinoid market is expected to grow significantly in the coming years and Amyris appears to be well-positioned to be a major player.
  • Amyris' current valuation really only reflects their Biossance brand, with little value attributed to high potential products like cannabinoids.

Glass bottles containing hemp oil, drugs extracted CBD Cannabis Oil of researchers or medical team. Herbal alternative medicine.

Tinnakorn Jorruang/iStock via Getty Images

Amyris (AMRS) is a leading synthetic biology manufacturer that uses fermentation to convert sugar into pure and sustainably sourced commercial molecules. Synthetic biology products are supplied as ingredients to customers as well as used in

This article was written by

8.84K Followers
Richard Durant is the leader of Narweena, an asset manager focused on finding market dislocations that are the result of a poor understanding of a businesses long-term prospects. Narweena believes that excess risk adjusted returns can be achieved by identifying businesses with secular growth opportunities in markets with barriers to entry. Narweena’s research process is focused on company and industry fundamentals with the goal of uncovering unique insights. Narweena has a high risk appetite and a long-term horizon, in pursuit of stocks that are deeply undervalued. Coverage tilts towards smaller cap stocks and markets where competitive advantages are not obvious.Investments are driven by a belief that an aging population with low population growth and stagnating productivity growth will create a different opportunity set to what has worked in the past. Many industries are likely to face stagnation or secular decline, which counter-intuitively may improve business performance if competition decreases. Conversely, other businesses are likely to face rising costs and diseconomies of scale. In addition, economies are becoming increasingly dominated by asset light businesses, and the need for infrastructure investments is declining over time. As a result, a large pool of capital is chasing a limited set of investment opportunities, which is driving up asset prices and compressing risk premia over time.Durant has undergraduate degrees in engineering and finance from the University of Adelaide (Honors) and an MBA from Nanyang Technological University (Dean’s Honors List). He has also passed the CFA exams.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of AMRS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About AMRSQ Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on AMRSQ

Related Stocks

SymbolLast Price% Chg
AMRSQ
--